Role of endoscopic ultrasound fine-needle aspiration evaluating adrenal gland enlargement or mass

Melissa Martinez; Julia LeBlanc; Mohammad Al-Haddad; Stuart Sherman; John DeWitt

doi:10.5527/wjn.v3.i3.92

Role of endoscopic ultrasound fine-needle aspiration evaluating adrenal gland enlargement or mass

World J Nephrol. 2014 Aug 6;3(3):92-100. doi: 10.5527/wjn.v3.i3.92.

Authors

Melissa Martinez¹, Julia LeBlanc¹, Mohammad Al-Haddad¹, Stuart Sherman¹, John DeWitt¹

Affiliation

¹ Melissa Martinez, Julia LeBlanc, Mohammad Al-Haddad, Stuart Sherman, John DeWitt, Department of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States.

Abstract

Aim: To report the clinical impact of adrenal endoscopic ultrasound fine-needle aspiration (EUS-FNA) in the evaluation of patients with adrenal gland enlargement or mass.

Methods: In a retrospective single-center case-series, patients undergoing EUS-FNA of either adrenal gland from 1997-2011 in our tertiary care center were included. Medical records were reviewed and results of EUS, cytology, adrenal size change on follow-up imaging ≥ 6 mo after EUS and any repeat EUS or surgery were abstracted. A lesion was considered benign if: (1) EUS-FNA cytology was benign and the lesion remained < 1 cm from its original size on follow-up computed tomography (CT), magnetic resonance imaging or repeat EUS ≥ 6 mo after EUS-FNA; or (2) subsequent adrenalectomy and surgical pathology was benign.

Results: Ninety-four patients had left (n = 90) and/or right (n = 5) adrenal EUS-FNA without adverse events. EUS indications included: cancer staging or suspected recurrence (n = 31), pancreatic (n = 20), mediastinal (n = 10), adrenal (n = 7), lung (n = 7) mass or other indication (n = 19). Diagnoses after adrenal EUS-FNA included metastatic lung (n = 10), esophageal (n= 5), colon (n = 2), or other cancer (n = 8); benign primary adrenal mass or benign tissue (n = 60); or was non-diagnostic (n = 9). Available follow-up confirmed a benign lesion in 5/9 non-diagnostic aspirates and 32/60 benign aspirates. Four of the 60 benign aspirates were later confirmed as malignant by repeat biopsy, follow-up CT, or adrenalectomy. Adrenal EUS-FNA diagnosed metastatic cancer in 24, and ruled out metastasis in 10 patients. For the diagnosis of malignancy, EUS-FNA of either adrenal had sensitivity, specificity, positive predictive value and negative predictive value of 86%, 97%, 96% and 89%, respectively.

Conclusion: Adrenal gland EUS-FNA is safe, minimally invasive and a sensitive technique with significant impact in the management of adrenal gland mass or enlargement.

Keywords: Adrenal gland neoplasms/diagnosis; Adrenal gland neoplasms/secondary; Adrenal gland/ultrasonography; Adrenal glands/pathology; Biopsy; Endosonography; Fine-needle.